Drug

Melphalan

Established medicine

ResearchOngoing clinical research

Also known as 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine, 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine, 4-(Bis(2-chloroethyl)amino)-L-phenylalanine, Alanine Nitrogen Mustard+20 more

3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine, 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine, 4-(Bis(2-chloroethyl)amino)-L-phenylalanine, Alanine Nitrogen Mustard, Alkeran, Evomela, Hepzato, Ivra, L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine, L-PAM, L-Phenylalanine mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melfalano, Phenylalanine mustard, Phenylalanine nitrogen mustard, Sarcoclorin, p-Bis(beta-chloroethyl)aminophenylalanine, p-Di-(2-chloroethyl)amino-L-phenylalanine, p-L-Sarcolysin, p-N,N-bis(2-chloroethyl)amino-L-phenylalanine, p-N-Bis(2-chloroethyl)amino-L-phenylalanine, Melfalan.

RxNorm6718 ChEMBLCHEMBL852 ATCL01AA03UNIIQ41OR9510P

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Pilot Study of the Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant

Clinical trial2026-09-01Status changed to Active, not recruiting · ClinicalTrials.gov

MT2022-60: A Phase II Study of Pembrolizumab+ BEAM Conditioning Regimen Before Autologous Stem Cell Transplant (ASCT) Followed by Pembrolizumab Maintenance in Patients of Relapsed or Refractory Classic Hodgkin Lymphoma

Clinical trial2026-09-01Primary completion · ClinicalTrials.gov

Pharmacokinetic (PK)-Directed Dosing of Captisol Enabled Melphalan for Patients With Multiple Myeloma or Light Chain (AL) Amyloidosis Undergoing High Dose Therapy and Autologous Hematopoietic Progenitor Cell Transplant

Clinical trial2026-09-01Primary completion · ClinicalTrials.gov

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (ADAPT)

Clinical trial2026-09-01Primary completion · ClinicalTrials.gov

A Prospective Study of Optimal Cord Selection for Haplo-Cord Transplantation: Targeting the Inherited Paternal Antigen (IPA) and Matching for the Non-Inherited Maternal Antigen (NIMA)

Clinical trial2026-08-19Status changed to Completed · ClinicalTrials.gov

A Multicenter, Open-Label, Single Arm, Phase II Study of Daratumumab as Consolidation/Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Conditioning Prior to Ex-vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation

Clinical trial2026-06-30Results expected Q3 2026 · ClinicalTrials.gov

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

Clinical trial2026-06-30Results posted · ClinicalTrials.gov

Phase-2 Study of Vedolizumab Plus Post-Transplant Cyclophosphamide and Short Course Tacrolimus for Graft-versus-Host Disease Prevention After Reduced Intensity Conditioning Peripheral Blood Stem Cell Allogeneic Hematopoietic Cell Transplantation

Clinical trial2026-06-29Results expected Q4 2028 · ClinicalTrials.gov

A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis

Clinical trial2026-06-17Results expected Q2 2027 · ClinicalTrials.gov

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Clinical trial2026-06-03Results posted · ClinicalTrials.gov

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.

Research2013-10-18Annals of hematology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Melphalan

Aliases & brands

3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine4-(Bis(2-chloroethyl)amino)-L-phenylalanineAlanine Nitrogen MustardAlkeranEvomelaHepzatoIvraL-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanineL-PAML-Phenylalanine mustardL-SarcolysinL-Sarcolysin Phenylalanine mustardL-SarcolysineMelfalanoPhenylalanine mustardPhenylalanine nitrogen mustardSarcoclorinp-Bis(beta-chloroethyl)aminophenylalaninep-Di-(2-chloroethyl)amino-L-phenylalaninep-L-Sarcolysinp-N,N-bis(2-chloroethyl)amino-L-phenylalaninep-N-Bis(2-chloroethyl)amino-L-phenylalanineMelfalan

RxNorm CUI

6718

ChEMBL ID

CHEMBL852

ATC codes

L01AA03

UNII

Q41OR9510P